Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 19/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL957379 | 0.95 | GRIA2 (0.61) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL959922 | 0.89 | GRIA2 (0.64) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL956946 | 0.87 | GRIA2 (0.62) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL957875 | 0.78 | GRIA2 (0.54) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL3253671 | 0.76 | GRIA2 (1.00) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL959816 | 0.76 | GRIA2 (0.66) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL958834 | 0.74 | GRIA2 (0.56) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL961063 | 0.74 | GRIA2 (0.64) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL958701 | 0.73 | GRIA2 (0.54) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL962511 | 0.73 | GRIA2 (0.71) | GRIA2CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173820-B2 | Compounds which potentiate the AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2012-05-08 | — | — | US | claimed |
| US-20110021578-A1 | Compounds which Potentiate the AMPA Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2011-01-27 | — | — | US | claimed |
| US-8173820-B2 | Compounds which potentiate the AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-8173820-B2 | Compounds which potentiate the AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-20110021578-A1 | Compounds which Potentiate the AMPA Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| US-20110021578-A1 | Compounds which Potentiate the AMPA Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| WO-2009080637-A1 | COMPOUNDS WHICH POTENTIATE THE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021578-A1 | Compounds which Potentiate the AMPA Receptor and Uses Thereof in Medicine | GRIN1, GRM1, GRM2 | GRIA2 20/4885CYP1A2 1001/4885CYP2C19 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.